Novanta to Present at Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025
NOVTBOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, is scheduled to present at Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life
Novanta Announces Financial Results for the Second Quarter 2025
NOVTBOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2025. Financial Highlights Three Months Ended (In millions, except per share amounts) June 27, June 28, 2025 2024 GAAP Revenue $ 241.0 $ 235.9 Operating Income $ 14.9 $ 25.7 Net Income $ 4.5 $ 13.8 Diluted EPS $ 0.12 $ 0.38
Novanta to Present at the CJS Securities 25th Annual New Ideas Summer Conference on Thursday, July 10, 2025
NOVTBOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the Company), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the CJS Securities 25th Annual New Ideas Summer Conference on Thursday, July 10, 2025, in White Plains, New York. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial
Novanta Sees Q2 Adj EPS $0.68-$0.78 vs $0.75 Est; Sees Sales $230.000M-$240.000M vs $240.74M Est
NOVTNovanta Q1 Adj. EPS $0.74 Beats $0.67 Estimate, Sales $233.37M Beat $233.34M Estimate
NOVTBaird Maintains Neutral on Novanta, Lowers Price Target to $160
NOVTNovanta Expects FY25 Revenue Of ~$1B Vs $1.04B Est, Adj EPS Of $3.35-$3.55 Vs $3.79 Est
NOVTNovanta Expects Q1 Revenue Of $232M-$236M Vs $244.89M Est, Adj EPS Of $0.63-$0.71 Vs $0.78 Est
NOVTNovanta Q4 2024 Adj. EPS $0.76 Beats $0.71 Estimate, Sales $238.060M Miss $240.287M Estimate
NOVTBaird Maintains Neutral on Novanta, Lowers Price Target to $169
NOVTNovanta Expects FY24 Revenue Of $948M-$953M (Prior $975M) Vs $973.08M Est, Adj EPS Of $3.02-$3.06 (Prior $3.20-$3.35) Vs $3.29 Est
NOVTNovanta Expects Q4 Revenue Of $237M-$242M Vs $242.33M Est, Adj EPS Of $0.70-$0.74 Vs $0.85 Est
NOVTNovanta Q3 2024 Adj. EPS $0.85, Inline, Sales $244.405M Beat $242.327M Estimate
NOVT